Wire · opportunities
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Cambrex's High Point facility in North Carolina has passed pre-approval inspections by the FDA, PMDA, and TGA, enabling it to manufacture approved active pharmaceutical ingredients for the US, Japan, and Australia. This follows a $38 million expansion to support smaller-scale commercial production, including orphan drugs and precision medicines.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a clear route to supply smaller-scale, targeted therapies to major markets including the US, Japan, and Australia thanks to this regulatory clearance. Expanding commercial manufacturing capacity at High Point removes bottlenecks in launching niche and orphan drugs.
◆ Coverage
1 source · 25 Aug 2026
◆ Related on Wire
◆ Topics